{"task_id": "18ec4de4e5b17af6", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 56/464)", "text": "\nCLINICAL FEATURES (CONT\u2019D)\nAtrial Fibrillation\n41\n\n--- Page 63 ---\nACUTE MANAGEMENT (CONT\u2019D)\nOVERALL APPROACH\n\u0002\nUNSTABLE ATRIAL FIBRILLATION\nperform cardiover\nsion immediately\n\u0002\nSTABLE ATRIAL FIBRILLATION <48 HOUR\nrate con\ntrol\n(b blockers,\ncalcium\nchannel\nblockers,\ndigoxin) and consider rhythm control (DC cardi\noversion, amiodarone, propafenone, flecainide).\nNeed to be anticoagulated for 4 weeks post\ncardioversion\n\u0002\nSTABLE ATRIAL FIBRILLATION >48 HOUR OR UNKNOWN\nDURATION\nrate control (b blockers, calcium chan\nnel blockers, digoxin) and consider rhythm control\n(IV heparin ! TEE to exclude atrial thrombus !\ncardioversion within 24 h ! anticoagulate \u00044\nweeks; ALTERNATIVELY anticoagulate \u00043 weeks\n! cardioversion ! anticoagulate \u00044 weeks)\n\u0002\nTREAT\nUNDERLYING\nCAUSE/PRECIPITANT\ninfection,\nmyocardial infarction, ischemia, drugs, pulmonary\nembolism, thyrotoxicosis\nLONG TERM MANAGEMENT\nRATE CONTROL\naim for a resting heart rate <80\nand exercise heart rate <110. b blocker (propranolol\n10 30 mg PO TID QID, metoprolol 50 100 mg PO\nBID). Calcium channel blockers (diltiazem CD\n120 480 mg PO daily). Digitalis (digoxin 0.5 mg PO\n\u00041 dose, then 0.25 mg \u00042 doses q6 12h, then\n0.125 0.25 mg daily)\nRHYTHM CONTROL\nelective cardioversion (only\nafter a 3 week course of therapeutic anticoagulation\nor atrial thrombus excluded by TEE. Cardioversion\nshould be followed by 4 weeks of anticoagulation).\nAntiarrhythmics (amiodarone 200 400 mg PO daily,\nsotalol 80 160 mg PO BID, especially if CAD; flecainide\n50 mg PO q12h, especially if no structural heart\ndisease; propafenone 150 mg PO q8h, especially if\nno structural heart disease)\nCLOT CONTROL\nASA 81 mg daily if no other risk\nfactors (see CHADS2). Otherwise, warfarin 5 mg PO\ndaily within 72 hours and continue heparin until INR\nis between 2 and 3. Heparin is not required if no\nthrombosis\nPROCEDURES\nradiofrequency ablation of the\npulmonary veins (PVI). Radiofrequency ablation of\nAV node with insertion of a permanent pacemaker\nand long term anticoagulation as last resort. Surgical\n(corridor and maze procedures)\nTREATMENT ISSUES\nSTROKE RISK FACTORS IN PATIENTS WITH ATRIAL\nFIBRILLATION wCHADS2w\n\u0002 CHF (any history, 1 point)\n\u0002 HYPERTENSION (any history, 1 point)\n\u0002 AGE >75 (1 point)\nTREATMENT ISSUES (CONT\u2019D)\n\u0002 DIABETES (1 point)\n\u0002 STROKE OR TIA (2 points)\n\u0002\nRISK OF STROKE\n0 points=0.49%/year (lone AF),\n1=1.5%, 2=2.5%, 3=5.3%, 4=6.0%, 5 6=6.9%\n\u0002\nOTHER\nRISK\nFACTORS\nCAD,\nechocardiography\nabnormalities (atrial size >5 cm, LV dysfunction),\nrheumatic valve disease (RR 17). All mitral stenosis\nand HOCM patients with AF should have chronic\nanticoagulation\n\u0002\nRISK REDUCTION\nanticoagulation decreases risk of\nstroke by \b60% (consider warfarin if CHADS2\nscore \u00051). ASA decreases risk by \b30%\n\u0002\nRISK OF BLEEDING ON ANTICOAGULATION\n1.9% per\nyear of major bleed. Thus, only recommend antic\noagulation if risk of stroke \u00051.5% (i.e. at least one\nrisk factor)\nFACTORS INCREASING RISK OF BLEED WITH\nWARFARIN USE\nadvanced age (3 4% risk of sig\nnificant bleeding per year if age >80), recent\nhemorrhage, uncontrolled hypertension, alcohol\nbinge drinking or liver disease, cancer, renal insuffi\nciency,\nlow\nplatelets,\nASA/clopidogrel/NSAIDs\n(including COX 2 inhibitors). Note that risk of fall\nby itself is not a contraindication to warfarin use.\nWarfarin is teratogenic and should be avoided in\npregnancy\nIMPORTANT TOXICITIES OF AMIODARONE\n\u0002\nCARDIAC (5%)\nsinus bradycardia and AV nodal\nblock. QT prolongation leading to torsade de\npointes may rarely occur\n\u0002\nTHYROID\ncauses of hyperthyroidism (3%) include\namiodarone induced thyroiditis and Jod Basedow\nphenomenon (excess iodine with amiodarone\nallows increased synthesis of T4 in patients with\npre existing toxic nodules). Patients on amiodar\none may not develop classic symptoms of\nhyperthyroidism;\nhowever,\nrecurrence\nof\nAF\nshould prompt investigations. Hypothyroidism is\nmore common (20%)\n\u0002\nPULMONARY (<3%)\nchronic interstitial pneumo\nnitis (most common), cryptogenic organizing\npneumonia,\nARDS,\nand\nsolitary\npulmonary\nnodule. Histologically characterized by foamy\nmacrophages in the air space. DLCO is often\ndecreased. CT chest may show diffuse/localized\ninterstitial or alveolar opacities. Treat with ster\noids and stop amiodarone\n\u0002\nHEPATIC\n(15%)\nnon alcoholic\nsteatohepatitis\nwhich in severe cases may lead to cirrhosis\n\u0002\nNEUROLOGIC\n(30%)\nataxia,\ntremor,\nperipheral\npolyneuropathy, insomnia, and impaired memory\n\u0002\nVISION (100%)\ncorneal microdeposits may result\nin halo vision, photophobia, and blurred vision.\nOptic nerve injury (1 2%) may cause blindness\n42\nAtrial Fibrillation", "text_length": 4570, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 56/464)", "type": "chunk", "chunk_index": 55, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.310846", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.311625", "status": "complete", "chunks_added": 3}